+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Idiopathic Pulmonary Fibrosis Market by Therapeutic Class (Antifibrotics, Immunosuppressants), Route Of Administration (Inhalation, Injectable, Oral), Distribution Channel, End User - Global Forecast 2025-2030- Product Image
Idiopathic Pulmonary Fibrosis Market by Therapeutic Class (Antifibrotics, Immunosuppressants), Route Of Administration (Inhalation, Injectable, Oral), Distribution Channel, End User - Global Forecast 2025-2030- Product Image
Sale

Idiopathic Pulmonary Fibrosis Market by Therapeutic Class (Antifibrotics, Immunosuppressants), Route Of Administration (Inhalation, Injectable, Oral), Distribution Channel, End User - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 193 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 5889780
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Idiopathic Pulmonary Fibrosis (IPF) market is rapidly evolving, driven by innovation in therapeutic strategies and a shifting healthcare landscape. For senior decision-makers seeking clarity in a complex field, this report delivers actionable intelligence on clinical trends, technology adoption, regional differences, and market pathways shaping IPF management.

Market Snapshot: Idiopathic Pulmonary Fibrosis Market Growth and Outlook

The idiopathic pulmonary fibrosis market expanded from USD 3.65 billion in 2024 to USD 3.86 billion in 2025 and is projected to continue advancing at a CAGR of 5.50%, reaching USD 5.03 billion by 2030. Market momentum is buoyed by demand for disease-modifying agents, an increasing focus on patient-centric care, and regulatory incentives for rare disease drug development. There is also a visible shift in provider and payer priorities, with greater emphasis on therapeutic value, outcome data, and cost-effectiveness. This environment heightens the need for understandings grounded in evidence and tailored for evolving stakeholder requirements.

Scope & Segmentation of the Idiopathic Pulmonary Fibrosis Market

This report offers an in-depth breakdown of the idiopathic pulmonary fibrosis market, mapping key segments, distribution models, therapeutic innovations, and regional dynamics to empower effective strategy formulation.

  • Therapeutic Classes: Covers antifibrotics (including nintedanib and pirfenidone), immunosuppressants (such as corticosteroids like methylprednisolone and prednisone), and immunomodulators (notably azathioprine, mycophenolate mofetil).
  • Routes of Administration: Examines oral, inhalation, and injectable options, addressing relevance for both acute and chronic care scenarios.
  • Distribution Channels: Assesses landscape across hospital, retail, specialty, and online pharmacies for accessibility and service considerations.
  • End Users: Reviews utilization patterns linked to hospitals, ambulatory care centers, specialty clinics, and home healthcare facilities—reflecting care environment diversity for IPF patients.
  • Regional Coverage: Encompasses Americas (with granular U.S. state analysis and key Latin American countries), Europe, Middle East & Africa (including Western, Eastern Europe and emerging MENA markets), and Asia-Pacific (focused on China, India, Japan, and key Southeast Asian economies).
  • Key Industry Participants: Profiles leaders such as Boehringer Ingelheim International GmbH, F. Hoffmann-La Roche Ltd., Gilead Sciences, Galapagos NV, Novartis AG, AstraZeneca PLC, Pfizer Inc., Merck & Co., Johnson & Johnson, and Bristol-Myers Squibb.

Key Takeaways for Senior Decision-Makers

  • Momentum in antifibrotic and immunomodulatory innovation is transforming standard care protocols, moving beyond symptom control toward disease pathway modulation.
  • Regulatory shifts and payer emphasis on robust clinical outcomes are driving demand for solid evidence and advanced real-world data collection, particularly for value-based contracting.
  • Emergence of precision medicine, including use of biomarkers and genomic profiling, is enabling improved patient stratification and individualized treatment planning.
  • Novel delivery technologies and digital health platforms are addressing persistent barriers in patient adherence, therapeutic tolerability, and remote monitoring—contributing to enhanced engagement.
  • Regional differences in reimbursement models, government support, and infrastructure are influencing adoption rates and shaping local market access strategies.
  • Collaborative ventures between established pharmaceuticals and biotechnology innovators are accelerating clinical development, supplementing R&D pipelines through strategic partnerships and licensing.

Tariff Impact and Supply Chain Dynamics

Recent U.S. tariff policies have created challenges in the IPF supply chain by increasing costs for imported drug components, prompting manufacturers to review sourcing strategies and consider nearshoring. These headwinds affect pricing negotiations, rebate structures, and patient support programs, while selective tariff exemptions for critical supplies underscore the value of proactive policy engagement and agile supplier networks. Forward-looking companies are strengthening relationships with logistics and distribution partners to secure continuity and affordability of IPF therapeutics.

Methodology & Data Sources

Insights are grounded in a rigorous blend of primary interviews with clinicians, payers, trade, and supply experts, supplemented by secondary analysis of peer-reviewed publications, regulatory documents, clinical trials, and real-world policy updates. Findings are validated through triangulation and iterative expert reviews to ensure accuracy and strategic relevance.

Why This Report Matters for Leadership

  • Enables informed decision-making by distilling complex multi-regional trends and emerging clinical opportunities into clear, actionable guidance.
  • Supports commercial strategy, innovation, and risk mitigation through granular segmentation analysis, policy tracking, and robust competitor profiling.
  • Empowers leaders to align investment and operational plans with evolving regulatory, reimbursement, and market access frameworks specific to IPF.

Conclusion

The idiopathic pulmonary fibrosis market is poised for continued evolution, shaped by scientific progress, complex regulations, and rising demands for value-based outcomes. Strategic adaptability and collaboration will be critical as stakeholders seek to realize clinical, commercial, and patient benefits in a changing landscape.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Emergence of precision medicine approaches using genomic biomarkers to predict treatment response in idiopathic pulmonary fibrosis
5.2. Development of inhaled antifibrotic formulations to improve lung-targeted drug delivery and patient tolerability
5.3. Integration of real-world evidence data to refine IPF disease progression models and health economics assessments
5.4. Advancements in antifibrotic combination therapies targeting TGF-ß and PDGF pathways for synergistic efficacy
5.5. Application of machine learning algorithms to high-resolution CT imaging for earlier IPF diagnosis and prognosis stratification
5.6. Collaborative clinical trials investigating mesenchymal stem cell therapies for lung tissue regeneration in progressive IPF
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Idiopathic Pulmonary Fibrosis Market, by Therapeutic Class
8.1. Introduction
8.2. Antifibrotics
8.2.1. Nintedanib
8.2.2. Pirfenidone
8.3. Immunosuppressants
8.3.1. Corticosteroids
8.3.1.1. Methylprednisolone
8.3.1.2. Prednisone
8.3.2. Immunomodulators
8.3.2.1. Azathioprine
8.3.2.2. Mycophenolate Mofetil
9. Idiopathic Pulmonary Fibrosis Market, by Route Of Administration
9.1. Introduction
9.2. Inhalation
9.3. Injectable
9.4. Oral
10. Idiopathic Pulmonary Fibrosis Market, by Distribution Channel
10.1. Introduction
10.2. Hospital Pharmacies
10.3. Online Pharmacies
10.4. Retail Pharmacies
10.5. Specialty Pharmacies
11. Idiopathic Pulmonary Fibrosis Market, by End User
11.1. Introduction
11.2. Ambulatory Care Centers
11.3. Home Healthcare Facilities
11.4. Hospitals
11.5. Specialty Clinics
12. Americas Idiopathic Pulmonary Fibrosis Market
12.1. Introduction
12.2. United States
12.3. Canada
12.4. Mexico
12.5. Brazil
12.6. Argentina
13. Europe, Middle East & Africa Idiopathic Pulmonary Fibrosis Market
13.1. Introduction
13.2. United Kingdom
13.3. Germany
13.4. France
13.5. Russia
13.6. Italy
13.7. Spain
13.8. United Arab Emirates
13.9. Saudi Arabia
13.10. South Africa
13.11. Denmark
13.12. Netherlands
13.13. Qatar
13.14. Finland
13.15. Sweden
13.16. Nigeria
13.17. Egypt
13.18. Turkey
13.19. Israel
13.20. Norway
13.21. Poland
13.22. Switzerland
14. Asia-Pacific Idiopathic Pulmonary Fibrosis Market
14.1. Introduction
14.2. China
14.3. India
14.4. Japan
14.5. Australia
14.6. South Korea
14.7. Indonesia
14.8. Thailand
14.9. Philippines
14.10. Malaysia
14.11. Singapore
14.12. Vietnam
14.13. Taiwan
15. Competitive Landscape
15.1. Market Share Analysis, 2024
15.2. FPNV Positioning Matrix, 2024
15.3. Competitive Analysis
15.3.1. Boehringer Ingelheim International GmbH
15.3.2. F. Hoffmann-La Roche Ltd.
15.3.3. Gilead Sciences, Inc.
15.3.4. Galapagos NV
15.3.5. Novartis AG
15.3.6. AstraZeneca PLC
15.3.7. Pfizer Inc.
15.3.8. Merck & Co., Inc.
15.3.9. Johnson & Johnson
15.3.10. Bristol-Myers Squibb Company
16. ResearchAI
17. ResearchStatistics
18. ResearchContacts
19. ResearchArticles
20. Appendix
List of Figures
FIGURE 1. IDIOPATHIC PULMONARY FIBROSIS MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY THERAPEUTIC CLASS, 2024 VS 2030 (%)
FIGURE 6. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY THERAPEUTIC CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 10. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 14. AMERICAS IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 16. UNITED STATES IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. EUROPE, MIDDLE EAST & AFRICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. ASIA-PACIFIC IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. ASIA-PACIFIC IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. IDIOPATHIC PULMONARY FIBROSIS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 22. IDIOPATHIC PULMONARY FIBROSIS MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 23. IDIOPATHIC PULMONARY FIBROSIS MARKET: RESEARCHAI
FIGURE 24. IDIOPATHIC PULMONARY FIBROSIS MARKET: RESEARCHSTATISTICS
FIGURE 25. IDIOPATHIC PULMONARY FIBROSIS MARKET: RESEARCHCONTACTS
FIGURE 26. IDIOPATHIC PULMONARY FIBROSIS MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. IDIOPATHIC PULMONARY FIBROSIS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ANTIFIBROTICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ANTIFIBROTICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY NINTEDANIB, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY NINTEDANIB, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY PIRFENIDONE, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY PIRFENIDONE, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ANTIFIBROTICS, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ANTIFIBROTICS, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY METHYLPREDNISOLONE, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY METHYLPREDNISOLONE, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY PREDNISONE, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY PREDNISONE, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY CORTICOSTEROIDS, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOMODULATORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOMODULATORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY AZATHIOPRINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY AZATHIOPRINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY MYCOPHENOLATE MOFETIL, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY MYCOPHENOLATE MOFETIL, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY INHALATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY INHALATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY INJECTABLE, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ORAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY SPECIALTY PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY SPECIALTY PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY HOME HEALTHCARE FACILITIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY HOME HEALTHCARE FACILITIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. AMERICAS IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
TABLE 68. AMERICAS IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2030 (USD MILLION)
TABLE 69. AMERICAS IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ANTIFIBROTICS, 2018-2024 (USD MILLION)
TABLE 70. AMERICAS IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ANTIFIBROTICS, 2025-2030 (USD MILLION)
TABLE 71. AMERICAS IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
TABLE 72. AMERICAS IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2030 (USD MILLION)
TABLE 73. AMERICAS IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2024 (USD MILLION)
TABLE 74. AMERICAS IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY CORTICOSTEROIDS, 2025-2030 (USD MILLION)
TABLE 75. AMERICAS IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2024 (USD MILLION)
TABLE 76. AMERICAS IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2025-2030 (USD MILLION)
TABLE 77. AMERICAS IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 78. AMERICAS IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 79. AMERICAS IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 80. AMERICAS IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 81. AMERICAS IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 82. AMERICAS IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 83. AMERICAS IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 84. AMERICAS IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 85. UNITED STATES IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
TABLE 86. UNITED STATES IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2030 (USD MILLION)
TABLE 87. UNITED STATES IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ANTIFIBROTICS, 2018-2024 (USD MILLION)
TABLE 88. UNITED STATES IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ANTIFIBROTICS, 2025-2030 (USD MILLION)
TABLE 89. UNITED STATES IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
TABLE 90. UNITED STATES IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2030 (USD MILLION)
TABLE 91. UNITED STATES IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2024 (USD MILLION)
TABLE 92. UNITED STATES IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY CORTICOSTEROIDS, 2025-2030 (USD MILLION)
TABLE 93. UNITED STATES IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2024 (USD MILLION)
TABLE 94. UNITED STATES IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2025-2030 (USD MILLION)
TABLE 95. UNITED STATES IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 96. UNITED STATES IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 97. UNITED STATES IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 98. UNITED STATES IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 99. UNITED STATES IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 100. UNITED STATES IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 101. UNITED STATES IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 102. UNITED STATES IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 103. CANADA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
TABLE 104. CANADA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2030 (USD MILLION)
TABLE 105. CANADA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ANTIFIBROTICS, 2018-2024 (USD MILLION)
TABLE 106. CANADA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ANTIFIBROTICS, 2025-2030 (USD MILLION)
TABLE 107. CANADA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
TABLE 108. CANADA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2030 (USD MILLION)
TABLE 109. CANADA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2024 (USD MILLION)
TABLE 110. CANADA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY CORTICOSTEROIDS, 2025-2030 (USD MILLION)
TABLE 111. CANADA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2024 (USD MILLION)
TABLE 112. CANADA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2025-2030 (USD MILLION)
TABLE 113. CANADA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 114. CANADA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 115. CANADA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 116. CANADA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 117. CANADA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 118. CANADA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 119. MEXICO IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
TABLE 120. MEXICO IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2030 (USD MILLION)
TABLE 121. MEXICO IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ANTIFIBROTICS, 2018-2024 (USD MILLION)
TABLE 122. MEXICO IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ANTIFIBROTICS, 2025-2030 (USD MILLION)
TABLE 123. MEXICO IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
TABLE 124. MEXICO IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2030 (USD MILLION)
TABLE 125. MEXICO IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2024 (USD MILLION)
TABLE 126. MEXICO IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY CORTICOSTEROIDS, 2025-2030 (USD MILLION)
TABLE 127. MEXICO IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2024 (USD MILLION)
TABLE 128. MEXICO IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2025-2030 (USD MILLION)
TABLE 129. MEXICO IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 130. MEXICO IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 131. MEXICO IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 132. MEXICO IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 133. MEXICO IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 134. MEXICO IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 135. BRAZIL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
TABLE 136. BRAZIL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2030 (USD MILLION)
TABLE 137. BRAZIL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ANTIFIBROTICS, 2018-2024 (USD MILLION)
TABLE 138. BRAZIL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ANTIFIBROTICS, 2025-2030 (USD MILLION)
TABLE 139. BRAZIL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
TABLE 140. BRAZIL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2030 (USD MILLION)
TABLE 141. BRAZIL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2024 (USD MILLION)
TABLE 142. BRAZIL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY CORTICOSTEROIDS, 2025-2030 (USD MILLION)
TABLE 143. BRAZIL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2024 (USD MILLION)
TABLE 144. BRAZIL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2025-2030 (USD MILLION)
TABLE 145. BRAZIL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 146. BRAZIL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 147. BRAZIL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 148. BRAZIL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 149. BRAZIL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 150. BRAZIL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 151. ARGENTINA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
TABLE 152. ARGENTINA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2030 (USD MILLION)
TABLE 153. ARGENTINA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ANTIFIBROTICS, 2018-2024 (USD MILLION)
TABLE 154. ARGENTINA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ANTIFIBROTICS, 2025-2030 (USD MILLION)
TABLE 155. ARGENTINA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
TABLE 156. ARGENTINA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2030 (USD MILLION)
TABLE 157. ARGENTINA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2024 (USD MILLION)
TABLE 158. ARGENTINA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY CORTICOSTEROIDS, 2025-2030 (USD MILLION)
TABLE 159. ARGENTINA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2024 (USD MILLION)
TABLE 160. ARGENTINA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2025-2030 (USD MILLION)
TABLE 161. ARGENTINA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 162. ARGENTINA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 163. ARGENTINA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 164. ARGENTINA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 165. ARGENTINA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 166. ARGENTINA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 167. EUROPE, MIDDLE EAST & AFRICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
TABLE 168. EUROPE, MIDDLE EAST & AFRICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2030 (USD MILLION)
TABLE 169. EUROPE, MIDDLE EAST & AFRICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ANTIFIBROTICS, 2018-2024 (USD MILLION)
TABLE 170. EUROPE, MIDDLE EAST & AFRICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ANTIFIBROTICS, 2025-2030 (USD MILLION)
TABLE 171. EUROPE, MIDDLE EAST & AFRICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
TABLE 172. EUROPE, MIDDLE EAST & AFRICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2030 (USD MILLION)
TABLE 173. EUROPE, MIDDLE EAST & AFRICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2024 (USD MILLION)
TABLE 174. EUROPE, MIDDLE EAST & AFRICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY CORTICOSTEROIDS, 2025-2030 (USD MILLION)
TABLE 175. EUROPE, MIDDLE EAST & AFRICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2024 (USD MILLION)
TABLE 176. EUROPE, MIDDLE EAST & AFRICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2025-2030 (USD MILLION)
TABLE 177. EUROPE, MIDDLE EAST & AFRICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 178. EUROPE, MIDDLE EAST & AFRICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 179. EUROPE, MIDDLE EAST & AFRICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 180. EUROPE, MIDDLE EAST & AFRICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 181. EUROPE, MIDDLE EAST & AFRICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 182. EUROPE, MIDDLE EAST & AFRICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 183. EUROPE, MIDDLE EAST & AFRICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 184. EUROPE, MIDDLE EAST & AFRICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 185. UNITED KINGDOM IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
TABLE 186. UNITED KINGDOM IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2030 (USD MILLION)
TABLE 187. UNITED KINGDOM IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ANTIFIBROTICS, 2018-2024 (USD MILLION)
TABLE 188. UNITED KINGDOM IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ANTIFIBROTICS, 2025-2030 (USD MILLION)
TABLE 189. UNITED KINGDOM IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
TABLE 190. UNITED KINGDOM IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2030 (USD MILLION)
TABLE 191. UNITED KINGDOM IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2024 (USD MILLION)
TABLE 192. UNITED KINGDOM IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY CORTICOSTEROIDS, 2025-2030 (USD MILLION)
TABLE 193. UNITED KINGDOM IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2024 (USD MILLION)
TABLE 194. UNITED KINGDOM IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2025-2030 (USD MILLION)
TABLE 195. UNITED KINGDOM IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 196. UNITED KINGDOM IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 197. UNITED KINGDOM IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 198. UNITED KINGDOM IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 199. UNITED KINGDOM IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 200. UNITED KINGDOM IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 201. GERMANY IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
TABLE 202. GERMANY IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2030 (USD MILLION)
TABLE 203. GERMANY IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ANTIFIBROTICS, 2018-2024 (USD MILLION)
TABLE 204. GERMANY IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ANTIFIBROTICS, 2025-2030 (USD MILLION)
TABLE 205. GERMANY IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
TABLE 206. GERMANY IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2030 (USD MILLION)
TABLE 207. GERMANY IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2024 (USD MILLION)
TABLE 208. GERMANY IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY CORTICOSTEROIDS, 2025-2030 (USD MILLION)
TABLE 209. GERMANY IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2024 (USD MILLION)
TABLE 210. GERMANY IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2025-2030 (USD MILLION)
TABLE 211. GERMANY IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 212. GERMANY IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 213. GERMANY IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 214. GERMANY IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 215. GERMANY IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 216. GERMANY IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 217. FRANCE IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
TABLE 218. FRANCE IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2030 (USD MILLION)
TABLE 219. FRANCE IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ANTIFIBROTICS, 2018-2024 (USD MILLION)
TABLE 220. FRANCE IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ANTIFIBROTICS, 2025-2030 (USD MILLION)
TABLE 221. FRANCE IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
TABLE 222. FRANCE IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2030 (USD MILLION)
TABLE 223. FRANCE IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2024 (USD MILLION)
TABLE 224. FRANCE IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY CORTICOSTEROIDS, 2025-2030 (USD MILLION)
TABLE 225. FRANCE IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2024 (USD MILLION)
TABLE 226. FRANCE IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2025-2030 (USD MILLION)
TABLE 227. FRANCE IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 228. FRANCE IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 229. FRANCE IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 230. FRANCE IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 231. FRANCE IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 232. FRANCE IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 233. RUSSIA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
TABLE 234. RUSSIA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2030 (USD MILLION)
TABLE 235. RUSSIA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ANTIFIBROTICS, 2018-2024 (USD MILLION)
TABLE 236. RUSSIA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ANTIFIBROTICS, 2025-2030 (USD MILLION)
TABLE 237. RUSSIA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
TABLE 238. RUSSIA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2030 (USD MILLION)
TABLE 239. RUSSIA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2024 (USD MILLION)
TABLE 240. RUSSIA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY CORTICOSTEROIDS, 2025-2030 (USD MILLION)
TABLE 241. RUSSIA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2024 (USD MILLION)
TABLE 242. RUSSIA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2025-2030 (USD MILLION)
TABLE 243. RUSSIA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 244. RUSSIA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 245. RUSSIA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 246. RUSSIA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 247. RUSSIA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 248. RUSSIA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 249. ITALY IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
TABLE 250. ITALY IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2030 (USD MILLION)
TABLE 251. ITALY IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ANTIFIBROTICS, 2018-2024 (USD MILLION)
TABLE 252. ITALY IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ANTIFIBROTICS, 2025-2030 (USD MILLION)
TABLE 253. ITALY IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
TABLE 254. ITALY IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2030 (USD MILLION)
TABLE 255. ITALY IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2024 (USD MILLION)
TABLE 256. ITALY IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY CORTICOSTEROIDS, 2025-2030 (USD MILLION)
TABLE 257. ITALY IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2024 (USD MILLION)
TABLE 258. ITALY IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2025-2030 (USD MILLION)
TABLE 259. ITALY IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 260. ITALY IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 261. ITALY IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 262. ITALY IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 263. ITALY IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 264. ITALY IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 265. SPAIN IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
TABLE 266. SPAIN IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2030 (USD MILLION)
TABLE 267. SPAIN IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ANTIFIBROTICS, 2018-2024 (USD MILLION)
TABLE 268. SPAIN IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ANTIFIBROTICS, 2025-2030 (USD MILLION)
TABLE 269. SPAIN IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
TABLE 270. SPAIN IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2030 (USD MILLION)
TABLE 271. SPAIN IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2024 (USD MILLION)
TABLE 272. SPAIN IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY CORTICOSTEROIDS, 2025-2030 (USD MILLION)
TABLE 273. SPAIN IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2024 (USD MILLION)
TABLE 274. SPAIN IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2025-2030 (USD MILLION)
TABLE 275. SPAIN IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 276. SPAIN IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 277. SPAIN IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 278. SPAIN IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 279. SPAIN IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 280. SPAIN IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 281. UNITED ARAB EMIRATES IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
TABLE 282. UNITED ARAB EMIRATES IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2030 (USD MILLION)
TABLE 283. UNITED ARAB EMIRATES IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ANTIFIBROTICS, 2018-2024 (USD MILLION)
TABLE 284. UNITED ARAB EMIRATES IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ANTIFIBROTICS, 2025-2030 (USD MILLION)
TABLE 285. UNITED ARAB EMIRATES IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
TABLE 286. UNITED ARAB EMIRATES IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2030 (USD MILLION)
TABLE 287. UNITED ARAB EMIRATES IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2024 (USD MILLION)
TABLE 288. UNITED ARAB EMIRATES IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY CORTICOSTEROIDS, 2025-2030 (USD MILLION)
TABLE 289. UNITED ARAB EMIRATES IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2024 (USD MILLION)
TABLE 290. UNITED ARAB EMIRATES IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2025-2030 (USD MILLION)
TABLE 291. UNITED ARAB EMIRATES IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 292. UNITED ARAB EMIRATES IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 293. UNITED ARAB EMIRATES IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 294. UNITED ARAB EMIRATES IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 295. UNITED ARAB EMIRATES IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 296. UNITED ARAB EMIRATES IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 297. SAUDI ARABIA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
TABLE 298. SAUDI ARABIA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2030 (USD MILLION)
TABLE 299. SAUDI ARABIA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, B

Samples

Loading
LOADING...

Companies Mentioned

The major companies profiled in this Idiopathic Pulmonary Fibrosis market report include:
  • Boehringer Ingelheim International GmbH
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences, Inc.
  • Galapagos NV
  • Novartis AG
  • AstraZeneca PLC
  • Pfizer Inc.
  • Merck & Co., Inc.
  • Johnson & Johnson
  • Bristol-Myers Squibb Company

Table Information

Report AttributeDetails
No. of Pages193
PublishedAugust 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 3.86 Billion
Forecasted Market Value ( USD ) by 2030 $ 5.03 Billion
Compound Annual Growth Rate5.5%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Idiopathic Pulmonary Fibrosis Market Report 2025 - Product Image

Idiopathic Pulmonary Fibrosis Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Idiopathic Pulmonary Fibrosis - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2025 - 2030) - Product Image

Idiopathic Pulmonary Fibrosis - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2025 - 2030)

  • Report
  • 110 Pages
  • Global
From
Idiopathic Pulmonary Fibrosis - Global Strategic Business Report - Product Image

Idiopathic Pulmonary Fibrosis - Global Strategic Business Report

  • Report
  • 181 Pages
  • Global
From
Idiopathic Pulmonary Fibrosis Market Report: Trends, Forecast and Competitive Analysis to 2031 - Product Image

Idiopathic Pulmonary Fibrosis Market Report: Trends, Forecast and Competitive Analysis to 2031

  • Report
  • 150 Pages
  • Global
From
Pulmonary Fibrosis Treatment - Global Strategic Business Report - Product Image

Pulmonary Fibrosis Treatment - Global Strategic Business Report

  • Report
  • 376 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.